M3 Wake Research

Executive Summary

M3 Wake Research is a premier integrated clinical trial site network in the United States, founded in 1984 and headquartered in Raleigh, NC. With a patient-centric approach, the company operates multiple investigational sites across North America, specializing in patient recruitment and trial execution for biopharmaceutical, biotechnology, and medical device sponsors across diverse therapeutic areas. The company's long-standing reputation for quality and integrity has positioned it as a trusted partner in advancing medical discoveries. By leveraging a broad geographic footprint and deep expertise in clinical research, M3 Wake Research continues to support the development of innovative therapies, contributing to the acceleration of drug development timelines and improving patient access to clinical trials. Looking ahead, M3 Wake Research is poised to capitalize on growing demand for decentralized and hybrid clinical trials, as sponsors increasingly seek efficient patient recruitment and retention solutions. The company's established infrastructure and experience position it well to expand its site network, forge new strategic partnerships, and adopt advanced technologies like digital patient engagement platforms. While the clinical research organization (CRO) market faces consolidation, M3 Wake Research's independence and specialized focus may offer unique value to sponsors seeking high-quality data and streamlined trial execution. The company's ability to adapt to evolving regulatory and operational landscapes will be key to sustaining its competitive edge.

Upcoming Catalysts (preview)

• Q3 2026Major new multi-year partnership with a top-10 pharma company60% success
• Q2 2026Expansion into 3 new U.S. metro markets through site acquisitions50% success
• Q4 2026Launch of a proprietary digital patient recruitment platform40% success